Vernalis
Vernalis Limited is a commercial stage pharmaceutical company based in Cambridge, United Kingdom, focused on the research, development, and commercialization of pharmaceutical products for various medical disorders. The company offers several products, including Tuzistra XR for the U.S. prescription cough-cold market, Moxatag, a once-daily amoxicillin formulation for treating tonsillitis and pharyngitis, and frovatriptan for acute migraine treatment. Vernalis engages in developing and commercializing additional products through licensing agreements, emphasizing its strategy of combining internal research with collaborations with global pharmaceutical companies. Its research laboratories employ advanced techniques such as fragment-based approaches, structural biology, and medicinal chemistry to facilitate drug discovery. Established in 1988, Vernalis operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Top Stages
3 past transactions
Cita NeuroPharmaceuticals
Acquisition in 2005
Cita NeuroPharmaceuticals Inc. operates as a neuropharmaceutical company.
Ionix Pharmaceuticals
Acquisition in 2005
Ionix Pharmaceuticals, based in Cambridge UK, is a leader in the discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Using proprietary drug targets and state-of-the-art chemistry, the company is developing medicines that are designed to alleviate pain associated with trauma, operative procedures, and debilitating diseases such as arthritis, diabetes and multiple sclerosis. Ionix Pharmaceuticals is a privately held company and was founded in 2001.
Pintex Pharmaceuticals
Acquisition in 2005
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company based in Watertown, Massachusetts, specializing in the discovery and development of structure-based cancer therapeutics. Founded in May 1999 by Dr. Kun Ping Lu, Dr. Walter Gilbert, and Dr. Janusz Sowadski, the company focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a critical role in cancer progression. The foundation of Pintex's research and development is rooted in the extensive work conducted at the Salk Institute for Biological Studies and Harvard University, where significant patents and discoveries related to cancer treatment technologies were established. Through its innovative approach, Pintex aims to advance therapeutic options for cancer patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.